Friday, 19 Oct 2018

You are here

Does Gender Make a Difference in Axial Spondyloarthritis

Males and females can both be affected by axial spondyloarthritis (axSpA). A recent study shows that while there are some differences and similarities, HLA-B27 and imaging are still pivotal elements for diagnosis of axSpA in both genders.

The SPACE (SPondyloArthritis Caught Early) cohort was devised to assess adults with chronic back pain (CBP; duration ≥ 3 months and ≤ 2 years, age of onset < 45 years) and is the dataset for these analyses. 

From a total of 719 CBP patients, 275 were male and 444 were female. The subsequent diagnosis of axSpA was made in 53% of males and 35% of females. Thus males were more likely to be diagnosed with axSpA (OR 2.1, 95% CI 1.5–2.9).

Males differed from female axSpA patient by being younger at diagnosis (27.4  vs 29.5 years; p = 0.02), haveing more HLA-B27 positivity (80% vs 60%; p < 0.01) and more imaging positivity (MRI or radiograph sacroiliitis) (78% vs 64%; p = 0.01).

Women with SpA features did have the same symptom duration and were also HLA-B27+ (23%) and had  positive imaging studies 7% of the time.

In multivariate analyses, the diagnosis of axSpA was equally linked to HLA-B27 and imaging positivity in both sexes. Yet males and those who were HLA-B27+ were more likely to manifest imaging positivity.

These results do not endorse the need for separate diagnostic strategies for men and women with CBP.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Apremilast Succeeds in Scalp Psoriasis

Celgene has announced results from the phase 3 STYLE study, showing apremilast yielding significant improvement in moderate-to-severe scalp psoriasis. STYLE is a phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluating the efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis of the scalp. The study enrolled 303 people who were randomized 2:1 to receive apremilast 30 mg twice daily or placebo for the first 16 weeks.

Complementary Therapies in Psoriasis

A systematic review in Archives of Dermatology suggests that among complementary and alternative medicine (CAM) therapies, the most effective are indigo naturalis, curcumin, dietary modification, meditation, and acupuncture.

It is estimated that  nearly half of patients with psoriasis report they use CAM, although their benefits are unclear in psoriasis.

Biologic Therapies Improve Work Outcomes in Spondyloarthritis

A study from the British Society for Rheumatology Biologics Register in Axial Spondyloarthritis (BSRBR-AS) shows that biologic use significantly improves work productivity and overall activity impairment.

 

The BSRBR-AS registry analyzed 577 participants who were employed;  28% were started on biological therapy .

BMS Tyk 2 Inhibitor Benefits Psoriasis

The NEJM reports that an oral selecive Tyrosine kinase 2 (TYK2) inhibitor of TYK2 was shown to be superior to placebo in a 12 week trial in patients with active psoriasis.

Methotrexate's Low Efficacy in Cutaneous Psoriasis

In a prospective, double-blind, randomized placebo-controlled study, Warren et al. studied the effect of an intensified methotrexate (MTX) in chronic plaque psoriasis and showed MTX to be effective and superior to placebo.